MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
POTENTIAL MULTIBAGGER
Do You Own this Little-known Smallcap Stock? >> READ MORE
- Home
- Stock Quote (indian pharma)
- BIOCON
BIOCON Share Price 
(BICN)
Here is the latest stock price and chart of BIOCON . For more details, see the BIOCON company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jun 29, 2022 (Close) | ||
|---|---|---|---|
| Price (Rs)310.30 | Open (Rs) 313.00 | High (Rs) 315.15 | Low (Rs) 308.25 |
| % Change-1.87 | Volume 110,873 | Value (Rs) 34,423,445 | 52-Week H/L 414.30 / 308.25 |
| Live NSE Quotes | Jun 29, 2022 (Close) | ||
|---|---|---|---|
| Price (Rs)310.20 | Open (Rs) 314.90 | High (Rs) 315.15 | Low (Rs) 308.05 |
| % Change-1.82 | Volume 2,928,101 | Value (Rs) 909,625,617 | 52-Week H/L 414.40 / 308.05 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.87% | 1 Month -7.08% | 3 Months -9.68% | 1 Year -23.86% | 5 Years (CAGR)* -1.15% | 10 Years (CAGR)* 2.71% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 8.15 | P/E Ratio (x) 38.07 | Market Cap (Rs m) 372,546.18 | P/BV (x) 4.51 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
BIOCON Share Price Today:
BIOCON last traded price was down 1.9% to Rs 310.3 on the BSE. On the NSE, BIOCON last traded price was down 1.8% to Rs 310.2. The total volume of shares traded was 3.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.3%. And the benchmark S&P BSE SENSEX was at 53,027.0 (down 0.3%).
Over the last 30 days, the BIOCON share price is down 7.1%. And over the last one year, BIOCON share price is down 23.2%.
The current market capitalisation of BIOCON stands at Rs 372,546.18 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 60.64% stake in BIOCON , with no shares having been pledged. To know more, check out the latest shareholding pattern of BIOCON .
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
FAQs on BIOCON
What is the BIOCON share price today?
The last traded price of BIOCON was Rs 310.3 on the BSE, down 1.9% over the previous close. On the NSE, BIOCON last traded price was down 1.8% at Rs 310.2.
What is the market cap of BIOCON ?
The current market capitalisation of BIOCON stands at Rs 372,546 m.
What is the Earnings per share (EPS) of BIOCON ?
BIOCON had an EPS of Rs 8.2 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 2.8.
What is the PE Ratio and PB Ratio of BIOCON ?
What is the Dividend Yield of BIOCON ?
For the financial year 2021, BIOCON declared dividend amounting to Rs 0.0 per share. At the current price of Rs 310.3, this results in a dividend yield of 0.0%.
Today's Market
Sensex Ends 150 Points Lower, Nifty Falls Below 15,800; FMCG & Banking Stocks Witness Selling(Closing)
After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.
Related Views On News
5 Takeaways from Sun Pharma's Q4 Results (Views On News)
May 30, 2022It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Why Divi's Lab Share Price is Falling (Views On News)
May 24, 2022Here's why Divi's Lab's stock fell over 10% in two days.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)
Apr 13, 2022The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
More Views on NewsMost Popular
4 Sectors to Watch for Future Multibagger Stocks (Views On News)
Jun 17, 2022With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Best Monopoly Stocks to Own in 2022 
(Views On News)
Jun 18, 2022
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
Is it Time to Start Buying Stocks Selectively? (Profit Hunter)
Jun 16, 2022Some sectors have corrected by 50%. Do they merit a look?
The One Smallcap Stock I'll Recommend Now (Profit Hunter)
Jun 21, 2022This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
The Greatest Dividend Stock of All Time is... (Views On News)
Jun 16, 2022Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.
MoreOUR TOP 5 IDEAS
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - MARKSANS PHARMA. COMPARISON
COMPARE BIOCON WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.